Alnylam Pharmaceuticals (ALNY) Reports $3B 2025 Revenue Driven by 151% TTR Franchise Surge
Alnylam Pharmaceuticals reported 2025 total revenue of nearly $3 billion, marking an 81% year-over-year increase driven by the successful launch of Amphotra. The company issued optimistic 2026 guidance with projected net product sales between $4.9 billion and $5.3 billion as it expands its RNAi manufacturing platform and clinical pipeline.
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Moderna (MRNA) and NewAmsterdam Pharma Company (NAMS)
Healthcare companies Alnylam Pharma (ALNY), Moderna (MRNA), and NewAmsterdam Pharma Company (NAMS) have received analyst coverage. Alnylam Pharma was reiterated with a "Buy" rating and a $510 price target, showing a strong buy consensus. Moderna maintained a "Hold" rating, with analysts suggesting a downside, while NewAmsterdam Pharma Company was also reiterated with a "Buy" rating and a strong buy consensus, indicating a significant upside.
11,700 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Bought by Alberta Investment Management Corp
Alberta Investment Management Corp acquired 11,700 shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in Q3, valued at approximately $5.34 million. Despite the company missing EPS and revenue estimates in its recent quarter, analysts maintain a "Moderate Buy" rating with an average target price near $477.96. The article also notes significant insider selling, with 36,578 shares worth $12.4 million sold recently, while institutional investors hold a substantial 92.97% of the stock.
Alnylam Pharmaceuticals' (ALNY) "Buy" Rating Reaffirmed at HC Wainwright
HC Wainwright has reaffirmed a "Buy" rating for Alnylam Pharmaceuticals (ALNY) with a $510 price target, suggesting a significant upside. This comes despite the company missing EPS and revenue expectations in its most recent quarter, though revenue still saw substantial year-over-year growth. Insider share sales and high institutional ownership present mixed signals, but analysts generally maintain a "Moderate Buy" consensus for the stock.
Sell Alert: Yvonne Greenstreet Cashes Out $2.16M In Alnylam Pharmaceuticals Stock
Yvonne Greenstreet, CEO of Alnylam Pharmaceuticals (NASDAQ: ALNY), sold 6,958 shares of the company's stock for a total of $2,157,542, according to a recent SEC filing. The company shows strong revenue growth of 84.95% but has a high debt-to-equity ratio of 1.62 and its stock metrics suggest it may be overvalued relative to its peers. Investors are advised to view insider transactions as one part of a comprehensive analysis.
Alnylam’s First Profitable Year Tests Durability Of TTR RNAi Franchise
Alnylam Pharmaceuticals (NasdaqGS:ALNY) has achieved its first full year of profitability in 2025, driven by the success of its TTR franchise and expanded Amvuttra indication. The company is also investing in a new RNAi manufacturing platform and forming new industry partnerships to broaden its RNA therapeutics portfolio. Key challenges include reliance on its TTR franchise and effective capital allocation for R&D and manufacturing to sustain its growth.
Alnylam stock rating upgraded at Freedom Capital on AMVUTTRA growth
Freedom Capital Markets upgraded Alnylam Pharmaceuticals (NASDAQ:ALNY) stock to Buy from Hold, citing AMVUTTRA’s strong revenue growth despite lowering the price target due to near-term revenue and gross margin pressures. This upgrade reflects anticipated upside from the current share price, even with increasing competition in the TTR market. Other firms like RBC Capital and BofA Securities have also adjusted their price targets while maintaining positive ratings, highlighting Alnylam's commercial execution and future pipeline catalysts.
Vanguard Group Inc. Buys 268,313 Shares of Alnylam Pharmaceuticals, Inc. $ALNY
Vanguard Group Inc. increased its stake in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 2.0% in the third quarter, acquiring an additional 268,313 shares to own a total of 13,565,452 shares valued at approximately $6.19 billion. Despite the biopharmaceutical company missing its Q3 earnings expectations with EPS of $0.82 against an anticipated $1.43, and revenue of $1.10 billion compared to the expected $1.16 billion, revenue still significantly rose by 84.9% year-over-year. Analysts maintain a consensus "Moderate Buy" rating for ALNY with an average target price of $477.38, even as insiders have sold 19,177 shares totaling about $6.98 million over the last three months.
Principal Financial Group Inc. Sells 45,114 Shares of Alnylam Pharmaceuticals, Inc. $ALNY
Principal Financial Group Inc. has significantly reduced its stake in Alnylam Pharmaceuticals, Inc., selling 45,114 shares, which diminished their holdings by 89.3%. Despite Alnylam missing earnings and revenue estimates in its most recent quarter, analysts maintain a "Moderate Buy" rating with a consensus target price of $477.38. This comes amidst considerable insider selling, with CEO Yvonne Greenstreet and EVP Tolga Tanguler selling shares worth millions.
ABN Amro Investment Solutions Has $597,000 Stake in Alnylam Pharmaceuticals, Inc. $ALNY
ABN Amro Investment Solutions significantly reduced its stake in Alnylam Pharmaceuticals by 99.3% in Q3, now holding 1,310 shares valued at $597,000. Despite recent insider selling and a Q4 earnings miss, analysts largely maintain a "Moderate Buy" rating with an average target price of $477.38. Institutional investors collectively own 92.97% of the biopharmaceutical company's stock.
Shell Asset Management Co. Sells 4,478 Shares of Alnylam Pharmaceuticals, Inc. $ALNY
Shell Asset Management Co. reduced its stake in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 61.7% in Q3, selling 4,478 shares and retaining 2,779 shares valued at $1.267 million. Despite recent mixed Q4 earnings results and revised FY-2026 guidance, analysts largely maintain a bullish outlook with an average price target of $477.38 against the current trading price of $314. The biopharmaceutical company reported profitability for the first time, driven by strong Amvuttra sales, though it missed Q4 EPS and revenue estimates.
Aberdeen Group plc Sells 61,228 Shares of Alnylam Pharmaceuticals, Inc. $ALNY
Aberdeen Group plc reduced its stake in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 28.0% in the third quarter, selling 61,228 shares and now owning 157,396 shares valued at $71.72 million. Other institutional investors also adjusted their positions, and 92.97% of the company's stock is held by institutional investors. Alnylam Pharmaceuticals reported mixed Q4 2025 financial results, with positive sentiment around Amvuttra-driven revenue growth and profitability, but also neutral to negative sentiment regarding revised FY2026 guidance and execution risks.
Alnylam Pharmaceuticals (ALNY) Turns Profitable With Q4 EPS Of US$1.41 Challenging Bearish Narratives
Alnylam Pharmaceuticals (ALNY) has achieved profitability in Q4 FY 2025 with an EPS of US$1.41 and revenue exceeding US$1 billion, marking a significant shift from previous losses. The company's trailing twelve-month revenue reached US$3.7 billion with a net income of US$313.7 million, sparking debate between bullish investors who point to growing RNAi drug adoption and bearish perspectives concerned about the high P/E of 132.9x and concentration risks. Despite bearish caution, the recent profit turnaround challenges the bearish narrative that often starts from loss-making assumptions, indicating potential for sustained growth in RNAi therapies.
12,116 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Cibc World Market Inc.
Cibc World Market Inc. initiated a new position in Alnylam Pharmaceuticals (NASDAQ:ALNY) during the third quarter, acquiring 12,116 shares valued at approximately $5.53 million. While institutional investors have increased their holdings, company insiders have recently been net sellers. Despite missing Q4 consensus estimates for EPS and revenue, Alnylam reported significant year-over-year revenue growth and issued positive FY 2026 revenue guidance, leading analysts to maintain a "Moderate Buy" consensus rating with a target price around $477.
Alnylam Pharmaceuticals (ALNY) Turns Profitable With Q4 EPS Of US$1.41 Challenging Bearish Narratives
Alnylam Pharmaceuticals (ALNY) reported a profitable Q4 2025 with basic EPS of US$1.41 and net income of US$186.4 million, pushing its full-year 2025 revenue to US$3.7 billion and net income to US$313.7 million. This shift to profitability challenges previous bearish narratives, despite the company's high P/E ratio of 132.9x and ongoing concerns about sustaining growth and reliance on TTR therapies. Bullish outlooks highlight significant expected earnings and revenue growth, positioning the stock below analyst price targets and DCF fair value estimates.
Is Alnylam Pharmaceuticals (ALNY) One of the Best Upside Stocks to Invest In Right Now?
Alnylam Pharmaceuticals (ALNY) is noted as a strong upside stock by analysts despite recent price target adjustments. Bank of America and H.C. Wainwright maintained Buy ratings, with Barclays initiating coverage with an Overweight rating and a $527 price target, citing the company's TTR franchise and Alnylam 2030 strategy. The article suggests that while ALNY has potential, other AI stocks might offer greater upside with less risk.
Alnylam Pharmaceuticals (ALNY) Turns Profitable With Q4 EPS Of US$1.41 Challenging Bearish Narratives
Alnylam Pharmaceuticals (ALNY) has achieved profitability in Q4 FY 2025, reporting revenue over US$1 billion and basic EPS of US$1.41, alongside net income of US$186.4 million. The company's full-year profit of US$313.7 million challenges prior bearish narratives, despite its high P/E ratio of 132.9x relative to the biotech industry average. Investors are now evaluating how this shift to profitability will impact future margins and whether the company can sustain its high growth rates.
Is Alnylam Pharmaceuticals (ALNY) One of the Best Upside Stocks to Invest In Right Now?
Alnylam Pharmaceuticals (ALNY) is considered a top upside stock, despite recent price target reductions by Bank of America and H.C. Wainwright. These firms maintained Buy ratings, with analysts citing compelling upside as the company's TTR franchise scales and its 2030 strategy is implemented. Barclays also initiated coverage with an Overweight rating, expressing a positive outlook on the biotech sector for 2026.
Is It Time To Revisit Alnylam Pharmaceuticals (ALNY) After The Recent Share Price Pullback?
Alnylam Pharmaceuticals (ALNY) has seen a recent share price pullback despite strong long-term returns. A Discounted Cash Flow (DCF) analysis suggests the stock is significantly undervalued at $308, with an intrinsic value of $698.61 per share. However, its Price/Sales ratio of 12.70x sits slightly above the industry average and a calculated "Fair Ratio," indicating it might be overvalued by that metric.
ALNY Q4 Earnings Beat, Sales Miss Despite Y/Y Growth, Stock Down
Alnylam Pharmaceuticals (ALNY) reported mixed Q4 2025 results, with adjusted earnings of $1.25 per share beating estimates but total revenues of $1.10 billion missing expectations despite an 85% year-over-year increase. The stock was down 4.1% following the announcement. The revenue miss is attributed to elevated Wall Street expectations rather than a decline in underlying demand, especially given strong sales of its lead drug, Amvuttra, and other products.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2025 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. held its Q4 and Full Year 2025 Earnings Conference Call, reporting nearly $3 billion in total global net product revenues for 2025, an 81% growth from 2024, driven by the strong performance of Amvuttra. The company achieved GAAP profitability for the full year and announced new five-year goals, Alnylam 2030, focusing on global TTR leadership, sustainable innovation, and disciplined growth to achieve over 25% revenue CAGR and 30% non-GAAP operating margin by 2030. They also discussed pipeline progress, including three Phase 3 studies initiated in 2025, and reiterated 2026 revenue guidance between $4.9 billion and $5.3 billion.
Rhumbline Advisers Sells 3,988 Shares of Alnylam Pharmaceuticals, Inc. $ALNY
Rhumbline Advisers reduced its stake in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 2.0% in the third quarter, selling 3,988 shares and now holding 196,497 shares valued at $89.6 million. Despite missing Q4 EPS and revenue estimates, Alnylam reported an 84.9% year-over-year revenue increase, largely driven by AMVUTTRA, and provided a strong FY2026 revenue guidance of $5.3B–$5.8B. Analyst coverage remains predominantly positive with a "Moderate Buy" consensus and an average price target of $476.34.
Alnylam targets 25% revenue CAGR through 2030 amid AMVUTTRA launch momentum and pipeline expansion
Alnylam Pharmaceutical is projecting a 25% compound annual growth rate (CAGR) for its revenue through 2030, driven by the strong launch of its drug AMVUTTRA and the expansion of its clinical pipeline. The company is focusing on leveraging its RNAi therapeutics platform to introduce new treatments and expand its market presence, aiming for significant financial growth in the coming years.
Alnylam Pharmaceuticals (ALNY) Valuation Check After Swing To Profit On Strong 2025 Earnings
Alnylam Pharmaceuticals (ALNY) reported a significant swing to profit in Q4 and full year 2025, with revenues sharply increasing. Despite strong earnings, the stock has seen declines recently, leading to questions about its current valuation. The company is considered 34.5% undervalued by one narrative, largely due to the robust performance of its drug AMVUTTRA, though a sales-based pricing view suggests its market pricing looks richer compared to industry peers.
Needham & Company LLC Has Lowered Expectations for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price
Needham & Company LLC reduced its price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) from $529 to $510, while maintaining a "buy" rating, following an earnings and revenue miss. The biopharmaceutical company reported an EPS of $0.82 against an expected $1.43 and revenue of $1.10 billion versus an anticipated $1.16 billion. Despite an 84.9% year-over-year revenue increase, the stock fell, and the article notes recent insider selling by executives.
Earnings call transcript: Alnylam Q4 2025 beats EPS, misses revenue forecast
Alnylam Pharmaceuticals (NASDAQ: ALNY) reported Q4 2025 earnings, exceeding EPS expectations with $1.25 against a forecast of $1.19, but missed revenue projections by reporting $1.1 billion against an anticipated $1.15 billion. Despite the revenue miss, the company's full-year net product revenues grew 81% to nearly $3 billion, driven by the strong performance of AMVUTTRA. Alnylam projects 71% growth in 2026 net product revenue and aims for a 25% revenue compound annual growth rate through 2030, with plans to expand its RNAi delivery and clinical programs.
ALNYLAM PHARMACEUTICALS ($ALNY) Releases Q4 2025 Earnings
ALNYLAM PHARMACEUTICALS ($ALNY) released its Q4 2025 earnings, reporting $1.25 per share, which beat estimates, but revenue of $1.097 billion missed expectations. Insider trading activity showed significant sales by executives and board members, while institutional holdings saw both additions and reductions by major firms. Analysts generally maintain "Buy" or "Overweight" ratings for the stock, with a median price target of $509.0.
Krilogy Financial LLC Acquires New Stake in Alnylam Pharmaceuticals, Inc. $ALNY
Krilogy Financial LLC recently acquired a new position of 3,822 shares, valued at approximately $1.66 million, in Alnylam Pharmaceuticals, Inc. during the third quarter. This comes as institutional ownership in Alnylam stands at 92.97%, despite notable insider selling totaling over $12 million in the last 90 days. Analysts maintain a "Moderate Buy" consensus rating for ALNY with an average target price of $477.13, significantly higher than its current trading price of around $321.99.
ALNYLAM PHARMACEUTICALS, INC. SEC 10-K Report
Alnylam Pharmaceuticals, Inc. has released its 2025 10-K report, announcing profitability for the first time with total revenues of $3,713.9 million and a net income of $313.7 million. This success is primarily attributed to its TTR franchise, especially AMVUTTRA, alongside advancements in its RNAi therapeutics pipeline with over 20 clinical programs. The company faces challenges including intense market competition, reliance on collaborations, and the need to sustain profitability while executing its "Alnylam 2030" growth strategy.
Earnings Flash (ALNY) Alnylam Pharmaceuticals, Inc. Reports Q4 Revenue $1.10B, vs. FactSet Est of $1.15B
Alnylam Pharmaceuticals, Inc. (ALNY) announced its Q4 revenue of $1.10 billion, falling short of FactSet's estimate of $1.15 billion. The company also reported Q4 adjusted EPS of $1.25 per share and provided its 2026 outlook. Additional news includes recent insider share sales, an RBC price target cut, and plans for a $250 million investment in manufacturing.
Alnylam Pharmaceuticals Reports Net Income In Q4
Alnylam Pharmaceuticals, Inc. reported a significant turnaround in Q4, with net income of $111.5 million compared to a loss in the prior year. The company's total revenues reached $1.10 billion, and it projects total net product revenues for 2026 to be between $4.9 billion and $5.3 billion. Despite the strong earnings report, Alnylam shares dipped slightly in pre-market trading.
Envestnet Asset Management Inc. Has $54.25 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY
Envestnet Asset Management Inc. significantly increased its stake in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 24.2% in the third quarter, now holding 118,964 shares valued at $54.25 million. This institutional buying comes amidst notable insider selling, with executives disposing of shares worth over $24 million in the last 90 days. Despite the mixed sentiment from insiders, analysts maintain a "Moderate Buy" rating for Alnylam with an average price target of $477.13.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Consensus Rating of "Moderate Buy" from Analysts
Alnylam Pharmaceuticals (NASDAQ:ALNY) has received a consensus "Moderate Buy" rating from twenty-seven analysts, with twenty-two recommending a buy and five a hold. The average one-year price target is $477.13, significantly higher than the opening price of $328.16. Insider selling of shares occurred last quarter, though institutions and hedge funds hold a substantial majority of the stock.
Stock Alert: Alnylam Pharma Shares Up 6%
Alnylam Pharmaceuticals Inc. (ALNY) shares rose over 6% after reporting positive topline results from its HELIOS-A Phase 3 Study for vutrisiran, a treatment for hATTR amyloidosis with polyneuropathy. The company plans to submit a New Drug Application (NDA) to the FDA in early 2021 and regulatory filings in other countries, with a Marketing Authorisation Application (MAA) in the EU expected in late 2021.
Down 34% From All-Time Highs, Can Alnylam Pharmaceuticals Stock Finally Recover In 2026?
Alnylam Pharmaceuticals (ALNY) reported strong Q3 earnings with revenues up 103% year-over-year, driven by its TTR franchise and the AMVUTTRA cardiomyopathy launch. Despite this momentum, the stock is down 34% from its highs, trading at $328. A valuation model projects the stock could reach $559 by December 2027, representing a 70% total return, based on aggressive revenue growth and margin expansion, assuming a more conservative P/E multiple than historical averages.
Allianz Asset Management GmbH Decreases Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY
Allianz Asset Management GmbH reduced its stake in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 48.1% in the third quarter of 2025, selling 99,177 shares and retaining 106,816 shares valued at $48.7 million. Despite this, other institutions like Norges Bank and Vanguard Group have significant holdings, with institutional investors owning nearly 93% of the company's stock. Insider trading data shows executives sold 56,955 shares for approximately $24.1 million in the last quarter, with insiders now holding about 1.50% of the stock.
Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: Should You Buy?
Alnylam Pharmaceuticals (ALNY) is projected to report significant year-over-year earnings and revenue growth for the quarter ended December 2025, with an expected EPS increase of 1833.3% and revenue up 91.4%. However, the company's Earnings ESP is negative, suggesting analysts have become bearish, making an earnings beat less certain despite a Zacks Rank #3 (Hold). The article also highlights Exelixis (EXEL) as a strong earnings-beat candidate with a positive Earnings ESP and a Zacks Rank #1 (Strong Buy).
Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: Should You Buy?
Alnylam Pharmaceuticals (ALNY) is projected to report a significant year-over-year increase in earnings and revenue for the quarter ended December 2025. While analysts have raised their EPS estimates for ALNY, the company's negative Earnings ESP combined with a Zacks Rank of #3 makes it difficult to predict an earnings beat with confidence. In contrast, Exelixis (EXEL) is expected to beat consensus estimates due to its positive Earnings ESP and Strong Buy Zacks Rank.
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After New Revenue Outlook And Long Term Growth Targets
Alnylam Pharmaceuticals (ALNY) has updated its revenue outlook, projecting US$5.1 billion for the year and a 25% compound annual growth rate through 2030, exceeding consensus. Despite recent share price fluctuations, the stock is reportedly undervalued, trading 49% below an intrinsic value estimate and 36% under analyst targets. The company's P/S ratio is 14.5x, which is higher than the US Biotechs average and its peers, suggesting a potential premium even with the undervaluation.
Alnylam Pharmaceuticals (BIT:1ALNY) Price Target Decreased by 11.40% to 411.81
The average one-year price target for Alnylam Pharmaceuticals (BIT:1ALNY) has been reduced by 11.40% to €411.81 per share from €464.82. This new target represents a 29.09% increase from the latest reported closing price of €319.00 per share. The article also details the ownership stakes of several major institutional investors, including Capital World Investors and Capital Research Global Investors.
25,451 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Mediolanum International Funds Ltd
Mediolanum International Funds Ltd has acquired 25,451 shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) during the third quarter, a new stake valued at approximately $11.39 million. This purchase contributes to the biopharmaceutical company's high institutional ownership of nearly 93%. The article also highlights mixed analyst sentiment, recent insider selling, and Alnylam's "Alnylam 2030" plan projecting $5.3 billion in 2026 revenue, despite concerns about the stock trading below its key moving averages.
Analyst Views Diverge as Alnylam Pharmaceuticals, Inc. (ALNY) Targets $5.1B Revenue and Long-Term Growth
Analyst opinions on Alnylam Pharmaceuticals (ALNY) are split despite the company targeting $5.1 billion in revenue and 25% compound annual growth through 2030. RBC Capital reiterated an Outperform rating but cut its price target, acknowledging robust long-term growth prospects while Cantor Fitzgerald maintained a Neutral stance due to slowing Amvuttra sales and expected price declines. Alnylam Pharmaceuticals is a pioneer in RNA interference, developing innovative medicines for various diseases.
Analyst Views Diverge as Alnylam Pharmaceuticals, Inc. (ALNY) Targets $5.1B Revenue and Long-Term Growth
Alnylam Pharmaceuticals, Inc. (ALNY) is targeting $5.1 billion in revenue and a 25% compound annual growth rate through 2030, exceeding consensus estimates. While RBC Capital reiterated an Outperform rating despite a price target cut, Cantor Fitzgerald maintained a Neutral rating due to concerns about Amvuttra sales and pricing strategy. Alnylam is a pioneer in RNA interference technology for treating various diseases.
Morgan Stanley Issues Pessimistic Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price
Morgan Stanley reduced its price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) from $495 to $408, maintaining an "equal weight" rating, implying a 19.36% upside. Despite other analysts holding a "Moderate Buy" consensus with a higher average target of $477.13, the stock recently traded down and insiders have sold off significant shares. Institutional investors hold a large portion of the stock.
Bank of America Issues Pessimistic Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price
Bank of America recently lowered its price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) from $529 to $462, yet maintained a "buy" rating, indicating a potential 33% upside. Despite this adjustment, other analysts largely hold a "Moderate Buy" consensus with an average target of $479.92. The article highlights significant insider selling totaling over $24 million but notes that institutional investors hold a substantial 92.97% of the stock.
H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Cuts Target Price to $510
H.C. Wainwright analyst Patrick Trucchio has reiterated a buy rating for Alnylam Pharmaceuticals (ALNY.US) but has adjusted the target price down from $570 to $510. According to TipRanks data, this analyst has a 53.4% success rate and an average return of 32.0% over the past year. The information is provided for informational purposes and should not be considered investment advice.
H.C. Wainwright raises Alnylam Pharmaceuticals stock price target on TTR franchise potential
H.C. Wainwright increased its price target for Alnylam Pharmaceuticals (NASDAQ:ALNY) to $510.00 from $470.00, reiterating a Buy rating due to the strength of Alnylam's TTR franchise and its "Alnylam 2030" strategic plan. Although the firm moderated its forward estimates to account for post-launch normalization and increased R&D investment, it sees no erosion in demand for ATTR-CM treatment or competitive positioning. Alnylam's impressive 53.24% revenue growth supports an attractive risk-reward profile, despite a high P/E ratio, with InvestingPro suggesting the stock is slightly undervalued.
What Alnylam Pharmaceuticals (ALNY)'s Analyst Re-Rating on Amvuttra and Pipeline Prospects Means For Shareholders
Alnylam Pharmaceuticals has garnered analyst attention due to strong growth from products like AMVUTTRA, GIVLAARI, and OXLUMO, along with anticipated updates on Amvuttra and pipeline programs nucresiran and mivelsiran. Analysts connect improving profitability and an expanding clinical portfolio to a more durable growth profile for the company. However, despite this renewed confidence, the stock may still be trading above its fair value, with Wells Fargo issuing an "Equal Weight" stance and concerns about rising R&D spend and margin pressure remaining.
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results
Alnylam Pharmaceuticals, Inc. announced it will report its financial results for the fourth quarter and full year ending December 31, 2025, on Thursday, February 12, 2026, before market open. Following the release, management will host a conference call at 8:30 am ET to discuss the results and future expectations. A live audio webcast will be available on the Investors section of the company's website.
Wealth Enhancement Advisory Services LLC Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY
Wealth Enhancement Advisory Services LLC significantly increased its stake in Alnylam Pharmaceuticals (NASDAQ:ALNY) by 183.8% in Q3, now holding 14,525 shares valued at $6.675 million. This investment comes despite recent insider selling by executives, totaling over $24 million. Analysts maintain a "Moderate Buy" rating with an average target price of $485.21, though price targets show mixed revisions.
